Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Venezuela's humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region.

Grillet ME, Hernández-Villena JV, Llewellyn MS, Paniz-Mondolfi AE, Tami A, Vincenti-Gonzalez MF, Marquez M, Mogollon-Mendoza AC, Hernandez-Pereira CE, Plaza-Morr JD, Blohm G, Grijalva MJ, Costales JA, Ferguson HM, Schwabl P, Hernandez-Castro LE, Lamberton PHL, Streicker DG, Haydon DT, Miles MA, Acosta-Serrano A, Acquattela H, Basañez MG, Benaim G, Colmenares LA, Conn JE, Espinoza R, Freilij H, Graterol-Gil MC, Hotez PJ, Kato H, Lednicky JA, Martinez CE, Mas-Coma S, Morris JG Jr, Navarro JC, Ramirez JL, Rodriguez M, Urbina JA, Villegas L, Segovia MJ, Carrasco HJ, Crainey JL, Luz SLB, Moreno JD, Noya Gonzalez OO, Ramírez JD, Alarcón-de Noya B.

Lancet Infect Dis. 2019 May;19(5):e149-e161. doi: 10.1016/S1473-3099(18)30757-6. Epub 2019 Feb 21. Review. Erratum in: Lancet Infect Dis. 2019 Feb 27;:.

PMID:
30799251
2.

In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis.

Teixeira de Macedo Silva S, Visbal G, Lima Prado Godinho J, Urbina JA, de Souza W, Cola Fernandes Rodrigues J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2360-2373. doi: 10.1093/jac/dky229.

PMID:
29982734
3.

The long road towards a safe and effective treatment of chronic Chagas disease.

Urbina JA.

Lancet Infect Dis. 2018 Apr;18(4):363-365. doi: 10.1016/S1473-3099(17)30535-2. Epub 2018 Jan 16. No abstract available.

PMID:
29352705
4.

Pharmacodynamics and Follow-Up Period in the Treatment of Human Trypanosoma Cruzi Infections With Posaconazole.

Urbina JA.

J Am Coll Cardiol. 2017 Jul 11;70(2):299-300. doi: 10.1016/j.jacc.2017.03.611. No abstract available.

5.

Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.

Spósito PÁ, Mazzeti AL, de Oliveira Faria C, Urbina JA, Pound-Lana G, Bahia MT, Mosqueira VF.

Int J Nanomedicine. 2017 May 17;12:3785-3799. doi: 10.2147/IJN.S133708. eCollection 2017.

6.

Congenital Chagas' disease transmission in the United States: Diagnosis in adulthood.

Murillo J, Bofill LM, Bolivar H, Torres-Viera C, Urbina JA, Benhayon D, Torres JR.

IDCases. 2016 Aug 2;5:72-5. doi: 10.1016/j.idcr.2016.07.011. eCollection 2016.

7.

Benznidazole for Chronic Chagas' Cardiomyopathy.

Urbina JA, Gascon J, Ribeiro I.

N Engl J Med. 2016 Jan 14;374(2):189. doi: 10.1056/NEJMc1514453. No abstract available.

PMID:
26760095
8.

Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.

Urbina JA, McKerrow JH.

Antimicrob Agents Chemother. 2015 Dec;59(12):7923-4. doi: 10.1128/AAC.01714-15. No abstract available.

9.

Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.

de Macedo-Silva ST, Visbal G, Urbina JA, de Souza W, Rodrigues JC.

Antimicrob Agents Chemother. 2015 Oct;59(10):6402-18. doi: 10.1128/AAC.01150-15. Epub 2015 Aug 3.

10.

Population pharmacokinetics of benznidazole in adult patients with Chagas disease.

Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejía T, Urbina JA, Gascón J.

Antimicrob Agents Chemother. 2015;59(6):3342-9. doi: 10.1128/AAC.05018-14. Epub 2015 Mar 30.

11.

SQ109, a new drug lead for Chagas disease.

Veiga-Santos P, Li K, Lameira L, de Carvalho TM, Huang G, Galizzi M, Shang N, Li Q, Gonzalez-Pacanowska D, Hernandez-Rodriguez V, Benaim G, Guo RT, Urbina JA, Docampo R, de Souza W, Oldfield E.

Antimicrob Agents Chemother. 2015 Apr;59(4):1950-61. doi: 10.1128/AAC.03972-14. Epub 2015 Jan 12.

12.

Chagas disease and the london declaration on neglected tropical diseases.

Tarleton RL, Gürtler RE, Urbina JA, Ramsey J, Viotti R.

PLoS Negl Trop Dis. 2014 Oct 9;8(10):e3219. doi: 10.1371/journal.pntd.0003219. eCollection 2014 Oct. No abstract available.

13.

Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.

Urbina JA.

J Eukaryot Microbiol. 2015 Jan-Feb;62(1):149-56. doi: 10.1111/jeu.12184. Epub 2014 Nov 13. Review.

PMID:
25284065
14.

Squalene synthase as a target for Chagas disease therapeutics.

Shang N, Li Q, Ko TP, Chan HC, Li J, Zheng Y, Huang CH, Ren F, Chen CC, Zhu Z, Galizzi M, Li ZH, Rodrigues-Poveda CA, Gonzalez-Pacanowska D, Veiga-Santos P, de Carvalho TM, de Souza W, Urbina JA, Wang AH, Docampo R, Li K, Liu YL, Oldfield E, Guo RT.

PLoS Pathog. 2014 May 1;10(5):e1004114. doi: 10.1371/journal.ppat.1004114. eCollection 2014 May. Erratum in: PLoS Pathog. 2014 Jun;10(6):e1004239.

15.

The effect of 3-(biphenyl-4-yl)-3-hydoxyquinuclidine (BPQ-OH) and metronidazole on Trichomonas vaginalis: a comparative study.

Rocha DA, de Andrade Rosa I, Urbina JA, de Souza W, Benchimol M.

Parasitol Res. 2014 Jun;113(6):2185-97. doi: 10.1007/s00436-014-3871-3. Epub 2014 Apr 22.

PMID:
24752367
16.

In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis.

de Macedo-Silva ST, Urbina JA, de Souza W, Rodrigues JC.

PLoS One. 2013 Dec 23;8(12):e83247. doi: 10.1371/journal.pone.0083247. eCollection 2013.

17.

Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments.

Diniz Lde F, Urbina JA, de Andrade IM, Mazzeti AL, Martins TA, Caldas IS, Talvani A, Ribeiro I, Bahia MT.

PLoS Negl Trop Dis. 2013 Aug 15;7(8):e2367. doi: 10.1371/journal.pntd.0002367. eCollection 2013.

18.

Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

Buckner FS, Urbina JA.

Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242.

19.

Endogenous sterol biosynthesis is important for mitochondrial function and cell morphology in procyclic forms of Trypanosoma brucei.

Pérez-Moreno G, Sealey-Cardona M, Rodrigues-Poveda C, Gelb MH, Ruiz-Pérez LM, Castillo-Acosta V, Urbina JA, González-Pacanowska D.

Int J Parasitol. 2012 Oct;42(11):975-89. doi: 10.1016/j.ijpara.2012.07.012. Epub 2012 Aug 29.

PMID:
22964455
20.

Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi.

Veiga-Santos P, Barrias ES, Santos JF, de Barros Moreira TL, de Carvalho TM, Urbina JA, de Souza W.

Int J Antimicrob Agents. 2012 Jul;40(1):61-71. doi: 10.1016/j.ijantimicag.2012.03.009. Epub 2012 May 14.

21.

Kinetic analyses and inhibition studies reveal novel features in peptide deformylase 1 from Trypanosoma cruzi.

Rodrígues-Poveda CA, Pérez-Moreno G, Vidal AE, Urbina JA, González-Pacanowska D, Ruiz-Pérez LM.

Mol Biochem Parasitol. 2012 Mar-Apr;182(1-2):83-7. doi: 10.1016/j.molbiopara.2011.12.003. Epub 2011 Dec 22.

PMID:
22209909
22.

Antiproliferative, Ultrastructural, and Physiological Effects of Amiodarone on Promastigote and Amastigote Forms of Leishmania amazonensis.

de Macedo-Silva ST, de Oliveira Silva TL, Urbina JA, de Souza W, Rodrigues JC.

Mol Biol Int. 2011;2011:876021. doi: 10.4061/2011/876021. Epub 2011 Jun 13.

23.

Two squalene synthase inhibitors, E5700 and ER-119884, interfere with cellular proliferation and induce ultrastructural and lipid profile alterations in a Candida tropicalis strain resistant to fluconazole, itraconazole, and amphotericin B.

Ishida K, Visbal G, Rodrigues JC, Urbina JA, de Souza W, Rozental S.

J Infect Chemother. 2011 Aug;17(4):563-70. doi: 10.1007/s10156-010-0190-1. Epub 2011 Jan 25.

PMID:
21264486
24.

Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis.

Ishida K, Fernandes Rodrigues JC, Cammerer S, Urbina JA, Gilbert I, de Souza W, Rozental S.

Ann Clin Microbiol Antimicrob. 2011 Jan 21;10:3. doi: 10.1186/1476-0711-10-3.

25.

Ultrastructural alterations induced by Δ(24(25))-sterol methyltransferase inhibitors on Trichomonas vaginalis.

Rosa Ide A, Rocha DA, de Souza W, Urbina JA, Benchimol M.

FEMS Microbiol Lett. 2011 Feb;315(1):72-8. doi: 10.1111/j.1574-6968.2010.02178.x. Epub 2010 Dec 22.

26.

Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.

Adesse D, Azzam EM, Meirelles Mde N, Urbina JA, Garzoni LR.

Antimicrob Agents Chemother. 2011 Jan;55(1):203-10. doi: 10.1128/AAC.01129-10. Epub 2010 Nov 15.

27.

A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease.

Olivieri BP, Molina JT, de Castro SL, Pereira MC, Calvet CM, Urbina JA, Araújo-Jorge TC.

Int J Antimicrob Agents. 2010 Jul;36(1):79-83. doi: 10.1016/j.ijantimicag.2010.03.006. Epub 2010 May 7.

PMID:
20452188
28.

Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.

Diniz Lde F, Caldas IS, Guedes PM, Crepalde G, de Lana M, Carneiro CM, Talvani A, Urbina JA, Bahia MT.

Antimicrob Agents Chemother. 2010 Jul;54(7):2979-86. doi: 10.1128/AAC.01742-09. Epub 2010 Apr 19.

29.

Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J.

Am J Trop Med Hyg. 2010 Apr;82(4):583-7. doi: 10.4269/ajtmh.2010.09-0620.

30.

Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.

Urbina JA.

Acta Trop. 2010 Jul-Aug;115(1-2):55-68. doi: 10.1016/j.actatropica.2009.10.023. Epub 2009 Nov 10. Review.

PMID:
19900395
31.

New advances in the management of a long-neglected disease.

Urbina JA.

Clin Infect Dis. 2009 Dec 1;49(11):1685-7. doi: 10.1086/648073. No abstract available.

PMID:
19877968
32.

Ergosterol biosynthesis and drug development for Chagas disease.

Urbina JA.

Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:311-8.

33.

Growth inhibition and ultrastructural alterations induced by Delta24(25)-sterol methyltransferase inhibitors in Candida spp. isolates, including non-albicans organisms.

Ishida K, Rodrigues JC, Ribeiro MD, Vila TV, de Souza W, Urbina JA, Nakamura CV, Rozental S.

BMC Microbiol. 2009 Apr 20;9:74. doi: 10.1186/1471-2180-9-74.

34.

Eliminating Chagas disease: challenges and a roadmap.

Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gürtler RE.

BMJ. 2009 Apr 14;338:b1283. doi: 10.1136/bmj.b1283. No abstract available.

35.

Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone.

Torres-Santos EC, Sampaio-Santos MI, Buckner FS, Yokoyama K, Gelb M, Urbina JA, Rossi-Bergmann B.

J Antimicrob Chemother. 2009 Mar;63(3):469-72. doi: 10.1093/jac/dkn546. Epub 2009 Jan 28.

36.

Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.

Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ.

Antimicrob Agents Chemother. 2009 Jan;53(1):174-9. doi: 10.1128/AAC.00779-08. Epub 2008 Nov 10.

37.

In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.

Fernandes Rodrigues JC, Concepcion JL, Rodrigues C, Caldera A, Urbina JA, de Souza W.

Antimicrob Agents Chemother. 2008 Nov;52(11):4098-114. doi: 10.1128/AAC.01616-07. Epub 2008 Sep 2.

38.

Delta24(25)-sterol methenyltransferase: intracellular localization and azasterol sensitivity in Leishmania major promastigotes overexpressing the enzyme.

Jiménez-Jiménez C, Carrero-Lérida J, Sealey-Cardona M, Ruiz Pérez LM, Urbina JA, González Pacanowska D.

Mol Biochem Parasitol. 2008 Jul;160(1):52-9. doi: 10.1016/j.molbiopara.2008.03.010. Epub 2008 Apr 8.

PMID:
18485498
39.

The challenges of Chagas Disease-- grim outlook or glimmer of hope.

Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE.

PLoS Med. 2007 Dec;4(12):e332. No abstract available.

40.

Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action.

Gerpe A, Odreman-Nuñez I, Draper P, Boiani L, Urbina JA, González M, Cerecetto H.

Bioorg Med Chem. 2008 Jan 1;16(1):569-77. Epub 2007 Aug 21.

PMID:
17981471
41.

Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition.

Rodrigues JC, Bernardes CF, Visbal G, Urbina JA, Vercesi AE, de Souza W.

Protist. 2007 Oct;158(4):447-56. Epub 2007 Aug 24.

PMID:
17719843
42.

Quinuclidine derivatives as potential antiparasitics.

Cammerer SB, Jimenez C, Jones S, Gros L, Lorente SO, Rodrigues C, Rodrigues JC, Caldera A, Ruiz Perez LM, da Souza W, Kaiser M, Brun R, Urbina JA, Gonzalez Pacanowska D, Gilbert IH.

Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61. Epub 2007 Aug 20.

43.

Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives.

Sealey-Cardona M, Cammerer S, Jones S, Ruiz-Pérez LM, Brun R, Gilbert IH, Urbina JA, González-Pacanowska D.

Antimicrob Agents Chemother. 2007 Jun;51(6):2123-9. Epub 2007 Mar 19.

44.

Alterations on the growth and ultrastructure of Leishmania chagasi induced by squalene synthase inhibitors.

Granthon AC, Braga MV, Rodrigues JC, Cammerer S, Lorente SO, Gilbert IH, Urbina JA, de Souza W.

Vet Parasitol. 2007 May 15;146(1-2):25-34. Epub 2007 Mar 23.

PMID:
17367936
45.

Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies.

Sanz-Rodríguez CE, Concepción JL, Pekerar S, Oldfield E, Urbina JA.

J Biol Chem. 2007 Apr 27;282(17):12377-87. Epub 2007 Feb 28.

46.

The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ.

Antimicrob Agents Chemother. 2007 Apr;51(4):1359-64. Epub 2007 Jan 12.

47.

Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites.

Urbina JA.

Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S9-S16. Epub 2006 Aug 22. Review.

PMID:
16930650
48.

New azasterols against Trypanosoma brucei: role of 24-sterol methyltransferase in inhibitor action.

Gros L, Castillo-Acosta VM, Jiménez Jiménez C, Sealey-Cardona M, Vargas S, Manuel Estévez A, Yardley V, Rattray L, Croft SL, Ruiz-Perez LM, Urbina JA, Gilbert IH, González-Pacanowska D.

Antimicrob Agents Chemother. 2006 Aug;50(8):2595-601.

49.

Miltefosine: issues to be addressed in the future.

Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA.

Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S41-4. Epub 2006 Jun 5. Review.

PMID:
16750231
50.

Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors.

Silva DT, de Nazareth S L de Meirelles M, Almeida D, Urbina JA, Pereira MC.

Int J Antimicrob Agents. 2006 Jun;27(6):530-7. Epub 2006 May 18.

PMID:
16713188

Supplemental Content

Loading ...
Support Center